Stay updated on Pembrolizumab and TKI in CML MRD Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and TKI in CML MRD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and TKI in CML MRD Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    A site-wide banner announces NIH website transition updates and says that “Super Intelligence” is replacing “Artificial Intelligence” in some federal agency content.
    Difference
    1%
    Check dated 2026-10-24T11:29:01.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The site footer’s revision label changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T12:18:57.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-10T12:25:15.000Z thumbnail image
  4. Check
    35 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study record with a generic access-block page.
    Difference
    16%
    Check dated 2026-09-19T20:21:05.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    The revision label on the page has been updated from v3.6.5 to v3.6.6, signaling a new software release. This change does not modify the study details or user-facing content.
    Difference
    0.0%
    Check dated 2026-08-29T21:52:50.000Z thumbnail image
  6. Check
    77 days ago
    Change Detected
    Summary
    Revision updated from v3.6.4 to v3.6.5 to reflect a routine update to the page's software version.
    Difference
    0.0%
    Check dated 2026-08-08T22:43:45.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and TKI in CML MRD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and TKI in CML MRD Clinical Trial page.